Zydus receives EIR with VAI from USFDA


Pharma major Zydus Lifesciences Ltd on Monday said it received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad in Gujarat.

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI), company said in a filing with BSE.

The USFDA had inspected the facility from July 26 to August 5, 2022 which concluded with four observations.

The USFDA has indicated that the inspection is closed.